Price
Financials
Standalone, Rs crore| Mar 2006 | Jun 2007 15m | |
|---|---|---|
| Revenue from operations | 5 | 10 |
| Operating costs | 10 | 23 |
| EBITDA | -5 | -13 |
| EBITDA margin % | -104% | -134% |
| Depreciation & amortisation | 0 | 0 |
| Finance costs | 0 | 0 |
| Non-operating income | 1 | 26 |
| Pre-tax profit | -5 | 12 |
| Effective tax rate % | 0% | 0% |
| Profit after tax | -5 | 12 |
| Earnings per share (Rs) | ||
| Paid out as dividend % | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Revenue CAGR | % | % | % | 96% | ||
| Profit CAGR | % | % | % | 88% | ||
| Share price CAGR | % | % | % | % | ||
| Average return on equity | % | % | % | % |
| Mar 2006 | Jun 2007 | |
|---|---|---|
| Net block (property, plant) | 4 | 17 |
| Capital work in progress | 0 | 0 |
| Investments | 0 | 0 |
| Current & other assets | 8 | 10 |
| Total assets | 12 | 27 |
| Share capital | 5 | 5 |
| Reserves & surplus | -19 | 6 |
| Total debt | 21 | 10 |
| Other liabilities & provisions | 5 | 5 |
| Equity + liabilities | 12 | 27 |
| Mar 2006 | Jun 2007 | |
|---|---|---|
| Operating cash flow | 12 | |
| Investing cash flow | -0 | |
| Free cash flow (after capex) | 12 | |
| Financing cash flow | -11 | |
| Net change in cash | 1 | |
| Cash conversion (OCF / EBITDA) % | -93% |
| Mar 2006 | Jun 2007 | |
|---|---|---|
| Return on capital employed % | -2% | |
| Receivable days | 62 | 71 |
| Inventory days | 565 | 377 |
| Payable days | 130 | 108 |
| Cash cycle (days) | 497 | 340 |
| Working capital days | 263 | 147 |
Fundamentals
Market value₹ Cr.
Last price₹
Book value / share₹
Return on capital-2.05 %
Return on equity%
Dividend yield%
Face value₹ 10.0
Revenue CAGR (TTM)96%
Profit CAGR (TTM)88%
Standalone figures.
Not enough published statements to compute ratios.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Vysali Pharmaceuticals Ltd?
Vysali Pharmaceuticals Ltd (524290) has a market capitalisation of Rs Cr. at the close.